Actively Recruiting
Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (The MAMBO Study) Phase I
Led by Hospital Universitari Vall d'Hebron Research Institute · Updated on 2024-10-28
108
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
H
Hospital Universitari Vall d'Hebron Research Institute
Lead Sponsor
I
Instituto de Salud Carlos III
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying migraine disorders to identify traits in spontaneous migraine attacks that may help predict how well patients respond to treatment with sumatriptan. The research aims to find differences between patients who respond to sumatriptan and those who do not, allowing for more personalized treatment approaches. This observational study focuses on acute migraine treatment where some patients currently do not respond well to medication. Participants with episodic migraine will treat four spontaneous migraine attacks using a 50 milligram dose of sumatriptan. They will record headache characteristics and note whether the treatment was effective for each attack. The study does not involve randomization or placebo and is designed to observe natural responses to the medication. During the study, participants will register headache features and accompanying symptoms for four migraine attacks. Researchers will monitor the response to sumatriptan within 24 hours and evaluate migraine characteristics at the same time point. Participants' data will be collected through internet access and mail correspondence. The study is expected to end in December 2024 and involves adults aged 18 to 45 years.
CONDITIONS
Brief Title
Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (MAMBO) Phase I
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Migraine with or without aura diagnosis according to ICHD-3 criteria
- Fewer than 8 migraine days per month
- Ability to read, write, and understand instructions
- Access to the internet and a mail address
- Signed informed consent
You will not qualify if you...
- Currently using active preventive treatment for migraine
- Taking medications that affect the central nervous system
- Having serious physical or psychiatric conditions
- Having cardiovascular or liver disease
- Being pregnant or breastfeeding
- Having any contraindication to triptans
- Experiencing severe migraine attacks without prior response to triptans or NSAIDs
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote)
Duration - Duration depends on occurrence of 4 migraine attacks
Participants treat four spontaneous migraine attacks with sumatriptan 50 milligrams and register headache characteristics and treatment response.
Participants record details for each migraine attack and treatment response
Trial Site Locations
Total: 1 location
1
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Actively Recruiting
Research Team
M
Marta Torres-Ferrús, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here